Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper 2 – Gynaecological cancers

4101 - Lenvatinib (LEN) and Pembrolizumab (PEMBRO) in Advanced Endometrial Cancer (EC)

Date

29 Sep 2019

Session

Proffered Paper 2 – Gynaecological cancers

Presenters

Vicky Makker

Citation

Annals of Oncology (2019) 30 (suppl_5): v403-v434. 10.1093/annonc/mdz250

Authors

V. Makker1, M.H. Taylor2, C. Aghajanian3, A. Oaknin4, J. Mier5, A.L. Cohn6, M. Romeo Marin7, R. Bratos Lorenzo8, M.S. Brose9, C. DiSimone10, M.J. Messing11, D.E. Stepan12, C.E. Dutcus13, J. Wu14, E.V. Schmidt15, R.J. Orlowski16, P. Sachdev17, R. Shumaker18, A. Casado Herraez19

Author affiliations

  • 1 Medical Oncology, Memorial Sloan Kettering Cancer Center, 10065 - New York City/US
  • 2 Division Of Hematology & Medical Oncology, Oregon Health & Science University, 97210 - Portland/US
  • 3 Medical Oncology, Memorial Sloan Kettering Cancer Center, 10065 - New York/US
  • 4 Medical Oncology, Vall d'Hebron University Hospital, Vall d’Hebron Institute of Oncology, 08035 - Barcelona/ES
  • 5 Department Of Medicine, Beth Israel Deaconess Medical Center, 02215 - Boston/US
  • 6 Medical Oncology, Rocky Mountain Cancer Center, 80208 - Denver/US
  • 7 Medical Oncology, Catalan Institute of Oncology, 08916 - Badalona/ES
  • 8 Medical Oncology, MD Anderson Cancer Center Center Espana, 28033 - Madrid/ES
  • 9 Otorhinolaryngology: Head And Neck Surgery, Abramson Cancer Center, University of Pennsylvania, 19104 - Philadelphia/US
  • 10 Medical Oncology/hematolgy, Arizona Oncology Associates, 85711 - Tucson/US
  • 11 Gynecologic Oncology, Texas Oncology, 76022 - Bedford/US
  • 12 Clinical Research, Formerly of Eisai Inc., 07677 - Woodcliff Lake/US
  • 13 Clinical Research, Eisai Inc., NJ 07677 - Woodcliff Lake/US
  • 14 Biostatistics, Oncology Business Group, Eisai Inc., 07677 - Woodcliff Lake/US
  • 15 Early Oncology, Clinical Development, Merck & Co. Inc., 19454 - North Wales/US
  • 16 Clinical Research, Merck & Co. Inc., 07033 - Kenilworth/US
  • 17 Clinical Research, Eisai Inc., 07677 - Woodcliff Lake/US
  • 18 Clinical Pharmacology And Translational Medicine, Eisai Inc., 07677 - Woodcliff Lake/US
  • 19 Department Of Medical Oncology, San Carlos University Teaching Hospital, 28040 - Madrid/ES
More

Resources

Abstract 4101

Background

LEN is a multikinase inhibitor of VEGFR 1–3, FGFR 1–4, PDGFRα, RET, and KIT. PEMBRO is an anti-PD-1 antibody. We report final results of a cohort of patients (pts) with metastatic EC (data cutoff, Jan. 10, 2019) as part of an ongoing phase 1b/2 study evaluating LEN + PEMBRO in pts with selected solid tumours.

Methods

In this cohort of a multicenter, open-label study, pts with histologically confirmed metastatic EC and measurable disease who received ≤2 prior chemotherapies (unless discussed with the sponsor) were administered LEN (20 mg PO QD) plus PEMBRO (200 mg IV Q3W). Tumour assessments for the primary phase 2 endpoint (objective response rate at 24 weeks [ORRWK24]) and secondary endpoints were evaluated by investigators per immune-related (ir)RECIST. Secondary endpoints included ORR, progression-free survival, overall survival, and duration of response. Tumour responses were also assessed by independent imaging reviewers per irRECIST, RECIST 1.1, and modified RECIST 1.1, and by investigators per mRECIST 1.1.

Results

At data cutoff, 108 pts with previously treated (1 regimen: 53%; >1 regimen: 47%) EC (endometrioid: 51%; serous: 32%; FIGO grade 3: 70%) were enrolled and had a median follow-up of 18.7 months. 13% of pts had high microsatellite instability (MSI-H) or mismatch-repair deficient (dMMR) status. Efficacy outcomes are summarized in the table. Treatment-related adverse events (TRAEs) occurred in 105 (97%) pts (97 [90%] ≤ grade 3, 8 [7%] ≥ grade 4). TRAEs led to study-drug interruption of one or both drugs in 78 (72%) pts and dose reductions of LEN in 70 (65%) pts; 20 (19%) pts discontinued one or both drugs due to a TRAE. The most common ≥ grade 3 TRAEs were hypertension (32%), fatigue (8%), and diarrhea (7%).

Conclusions

The LEN + PEMBRO combination showed promising antitumor activity in metastatic EC regardless of MSI/MMR status. Treatment was generally well tolerated, and no new safety signals emerged. A phase 3 study in advanced EC is underway (NCT03517449).Table: 994O

Investigator assessment per irRECISTPreviously treated EC
Total (N = 108)Not MSI-H or dMMR (n = 94)MSI-H/dMMR (n = 11)
ORRWK24, n (%) 95% CI41 (38.0) 28.8–47.834 (36.2) 26.5–46.77 (63.6) 30.8–89.1
ORR, n (%) (95% CI) Complete response Partial response42 (38.9) 29.7–48.7 8 (7.4) 34 (31.5)35 (37.2) 27.5–47.8 7 (7.4) 28 (29.8)7 (63.6) 30.8–89.1 1 (9.1) 6 (54.5)
Median duration of response, months (95% CI)21.2 (7.6–NR)NE (7.4–NR)21.2 (7.3–NR)
Kaplan-Meier estimate of duration of response ≥6 months,a n Probability (95% CI)32 0.87 (0.72–0.95)25 0.85 (0.67–0.93)7 1.00 (NR–NR)
Median progression-free survival, months (95% CI)7.4 (5.3–8.7)7.4 (5.0–7.6)18.9 (4.0–NR)
Median overall survival, months (95% CI)16.7 (15.0–NR)16.4 (13.5–25.9)NR (7.4–NR)
Time to response (months), mean (SD)2.6 (1.6)2.5 (1.5)2.9 (1.8)
a

Probabilities of patients achieving a duration of response ≥6 months were calculated using the Kaplan-Meier product-limit method and Greenwood formula. CI, confidence interval; dMMR, mismatch repair deficient; NR, not reached; SD, standard deviation.

Clinical trial identification

NCT02501096.

Editorial acknowledgement

Jeffrey K. Bratz, PhD of Oxford PharmaGenesis, Newtown, PA was funded by Eisai Inc.

Legal entity responsible for the study

Eisai Inc.

Funding

Eisai Inc. and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

Disclosure

V. Makker: Non-remunerated activity/ies: AstraZeneca; Honoraria (self), Non-remunerated activity/ies: Eisai; Honoraria (self), Non-remunerated activity/ies: Merck; Non-remunerated activity/ies: Lilly; Honoraria (self), Non-remunerated activity/ies: Karyopharm; Honoraria (self), Non-remunerated activity/ies: Takeda; Non-remunerated activity/ies: Genentech. M.H. Taylor: Research grant / Funding (institution): BioAlta; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Bristol-Myers Squibb; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Array Biopharma; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Eisai; Honoraria (self), Travel / Accommodation / Expenses: Bayer; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: LOXO; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Blueprint; Honoraria (self), Advisory / Consultancy: Arquele; Honoraria (self), Advisory / Consultancy: Novartis. C. Aghajanian: Advisory / Consultancy: Tesaro; Advisory / Consultancy: Immunogen; Advisory / Consultancy, Research grant / Funding (self): Clovis; Honoraria (self): Mateon Therapeutics; Advisory / Consultancy: Cerulean Pharma; Research grant / Funding (self): Genentech. A. Oaknin: Travel / Accommodation / Expenses: Roche; Travel / Accommodation / Expenses: AstraZeneca; Research grant / Funding (institution), Travel / Accommodation / Expenses: PharmaMar; Research grant / Funding (institution), Travel / Accommodation / Expenses: Clovis Oncology; Honoraria (self), Research grant / Funding (institution): Tesaro; Honoraria (self), Research grant / Funding (institution): Immunogen; Research grant / Funding (institution): Eisai Ltd.; Research grant / Funding (institution): Merck Sharp & Dohme de España SA; Honoraria (self): Genmab; Research grant / Funding (institution): AbbVie Deutschland; Research grant / Funding (institution): Millennium Pharma; Research grant / Funding (institution): Regeneron Pharmaceuticals; Research grant / Funding (institution): Ability Pharmaceuticals; Research grant / Funding (institution): Advaxis Inc; Research grant / Funding (institution): Aeterna Zentaris; Research grant / Funding (institution): Amgen SA; Research grant / Funding (institution): Aprea Therapeutics AB; Research grant / Funding (institution): F. Hoffman - La Roche Ltd. M. Romeo Marin: Advisory / Consultancy: Tesoro; Advisory / Consultancy, Non-remunerated activity/ies: Roche; Speaker Bureau / Expert testimony: AstraZeneca. M.S. Brose: Honoraria (self): Eisai. D.E. Stepan: Full / Part-time employment: Formerly of Eisai Inc. C.E. Dutcus: Leadership role, Full / Part-time employment: Eisai Inc. J. Wu: Full / Part-time employment: Eisai Inc. E.V. Schmidt: Full / Part-time employment: Merck & Co Inc. R.J. Orlowski: Full / Part-time employment: Merck & Co Inc. P. Sachdev: Full / Part-time employment: Eisai Inc. R. Shumaker: Full / Part-time employment: Eisai Inc. A. Casado Herraez: Research grant / Funding (institution), Travel / Accommodation / Expenses: PharmaMar. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings